Enrolling

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

J2J-MC-JZLH -

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Breast Cancer
What the trial is testing?
Anastrozole, Exemestane, Imlunestrant, Letrozole, Tamoxifen
Could I receive a Placebo?
No
Enrollment Goal
6000
Trial Dates
Oct 4, 2022 - Mar 2032
How long will I be in the trial?
Study participation could last up to 10 years.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have early-stage ER+ HER2- breast cancer
  • Have already had surgery to treat the breast cancer
  • Have higher-than-average risk for the breast cancer to come back
  • Have been taking a drug that blocks the production/action of estrogen for the last two to five years
  • Be able to walk and able to carry out light work
  • Have adequate body organ function

Participants Must Not:

  • Have breast cancer that is advanced or has spread to another part(s) of the body
  • Have a serious medical condition (other than this cancer)

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources